Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 22492981)

1.

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.

Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM.

Clin Cancer Res. 2012 Jun 1;18(11):3197-206. doi: 10.1158/1078-0432.CCR-12-0056. Epub 2012 Apr 5.

2.

Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.

Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM.

Mol Pharm. 2011 Dec 5;8(6):2080-8. doi: 10.1021/mp200240a. Epub 2011 Jul 15.

3.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2005 Nov 1;23(31):7911-8. Epub 2005 Oct 3.

4.

Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.

Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE, Straughn JM, Buchsbaum DJ, Grizzle WE, McNally LR.

Ann Surg Oncol. 2013 Sep;20(9):3059-65. doi: 10.1245/s10434-013-2878-9. Epub 2013 Mar 24.

PMID:
23525731
5.

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.

Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G.

BMC Cancer. 2009 Oct 18;9:368. doi: 10.1186/1471-2407-9-368.

6.

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.

Clin Cancer Res. 2005 Aug 15;11(16):6030-9.

7.

Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.

Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y.

Oncol Rep. 2011 Apr;25(4):1131-8. doi: 10.3892/or.2011.1151. Epub 2011 Jan 18.

PMID:
21249319
8.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

9.

Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.

Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G.

Anticancer Res. 2010 Nov;30(11):4451-8.

PMID:
21115892
10.

Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.

Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.

Gynecol Oncol. 2014 Sep;134(3):591-8. doi: 10.1016/j.ygyno.2014.06.025. Epub 2014 Jul 1.

PMID:
24995581
11.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

12.

Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.

Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D'Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA.

Endocr Relat Cancer. 2009 Dec;16(4):1241-9. doi: 10.1677/ERC-08-0342. Epub 2009 Sep 11.

13.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.

Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Clin Exp Metastasis. 2014 Jan;31(1):101-10. doi: 10.1007/s10585-013-9614-5. Epub 2013 Sep 5.

14.

Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.

Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA.

Int J Gynecol Cancer. 2012 May;22(4):566-72. doi: 10.1097/IGC.0b013e318247727f.

PMID:
22426404
15.

Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.

Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR.

Mod Pathol. 2011 Mar;24(3):453-62. doi: 10.1038/modpathol.2010.211. Epub 2010 Nov 19.

16.

Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.

Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y.

Oncol Rep. 2006 May;15(5):1265-71.

PMID:
16596196
17.

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.

Salani R, Kurman RJ, Giuntoli R 2nd, Gardner G, Bristow R, Wang TL, Shih IM.

Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91. Epub 2007 Aug 10.

PMID:
17692090
18.

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.

Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31.

19.
20.

ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.

Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R.

Anticancer Res. 2014 Jan;34(1):393-9.

PMID:
24403493
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk